Regeneron Pharmaceuticals, Inc.REGNNASDAQ
Loading

Latest News

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
seekingalpha.com

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

Why Dupixent Keeps Regeneron A Top Big Pharma Pick
seekingalpha.com

Why Dupixent Keeps Regeneron A Top Big Pharma Pick

Regeneron Pharmaceuticals ended 2025 and started this year on a high note. Regeneron and its partner Sanofi are among the leaders in the immune-mediated inflammatory diseases market. In Q4, Dupixent sales grew 22.8% year-on-year and 2.2% quarter-on-quarter to about €4.25 billion.

Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique
globenewswire.com

Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique

Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans et plus, appuyée par une étude de phase 3 démontrant que Dupixent a réduit de manière significative les signes et symptômes nasaux ainsi que le recours aux corticostéroïdes systémiques ou à la chirurgie par rapport au placebo L'AFRS est une maladie inflammatoire chronique de type 2 des sinus caractérisée par une hypersensibilité allergique aux champignons qui nécessite souvent une intervention chirurgicale avec des taux élevés de récidive postopératoire Dupixent est maintenant approuvé aux États-Unis pour traiter neuf maladies chroniques, dues notamment à une inflammation de type 2 Dupixent est désormais approuvé aux États-Unis pour le traitement de neuf maladies distinctes liées en partie à l'inflammation de type 2, notamment des maladies sino-nasales, cutanées, gastro-intestinales et respiratoires touchant un large éventail de patients, du nourrisson à la personne âgée Paris et Tarrytown, NY, le 24 février 2026.

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
globenewswire.com

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the US to treat nine distinct diseases driven in part by type 2 inflammation, including sino-nasal, skin, gut and respiratory system diseases that affect a broad range of patients, from infants to elderly adults Paris and Tarrytown, NY, February 24, 2026. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery.

Regeneron Pharmaceuticals (NASDAQ:REGN) Director Huda Zoghbi Sells 1,638 Shares
defenseworld.net

Regeneron Pharmaceuticals (NASDAQ:REGN) Director Huda Zoghbi Sells 1,638 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) Director Huda Zoghbi sold 1,638 shares of the firm's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares in the

Lansforsakringar Fondforvaltning AB publ Has $21.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN
defenseworld.net

Lansforsakringar Fondforvaltning AB publ Has $21.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Lansforsakringar Fondforvaltning AB publ increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 3.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,325 shares of the biopharmaceutical company's stock after purchasing an additional 1,365 shares during the

Citigroup Inc. Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN
defenseworld.net

Citigroup Inc. Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Citigroup Inc. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 25.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,191 shares of the biopharmaceutical company's stock after selling 46,055 shares during the